* Mesa Laboratories Inc MLAB.OQ MLAB.O is expected
to show a
rise in quarterly revenue when it reports results on November 2
(estimated).
* The Lakewood Colorado-based company is expected to report
a
48.7% increase in revenue to $53.3 million from $35.84 million a
year ago, according to the mean estimate from 3 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Mesa Laboratories
Inc is
for a loss of 31 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Mesa
Laboratories
Inc is $180, above its last closing price of $135.81.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 0.91 1.00 -0.27 Missed -127.1
Mar. 31 2022 0.48 0.48 -0.34 Missed -170.8
Dec. 31 2021 0.42 0.42 0.61 Beat 45.2
Sep. 30 2021 0.50 0.42 0.70 Beat 66.7
Jun. 0.11 0.10 0.38 Beat 280
30 2021
Mar. 31 2021 0.18 0.26 0.74 Beat 190.2
Dec. 31 2020 0.32 0.33 -0.89 Missed -373.8
Sep. 30 2020 0.04 0.06 0.51 Beat 705.3
This summary was machine generated October 31 at 18:33 GMT. All
figures in US dollars unless otherwise stated